Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Herold

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Haematologica|December 22, 2018
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
British Journal of Haematology|April 22, 2008
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patientsCarsten Hirt, Frank Schüler, Thomas Kiefer, et al.
Toxicology Letters|October 9, 2021
Use of in vitro metabolomics in NRK cells to help predicting nephrotoxicity and differentiating the MoA of nephrotoxicantsBarbara Birk, Volker Haake, Saskia Sperber, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Archives of Toxicology|October 2, 2017
Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cellsTzutzuy Ramirez, Alexander Strigun, Andreas Verlohner, et al.
Cell Biology and Toxicology|May 3, 2023
A high-throughput metabolomics in vitro platform for the characterization of hepatotoxicitySabina Ramirez-Hincapie, Barbara Birk, Philipp Ternes, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 31, 2022
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical TrialsJesse G Dixon, Çağlar Çağlayan, Dai Chihara, et al.
The New England Journal of Medicine|October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular LymphomaRobert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Blood|October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trialsCarla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Haematologica|December 22, 2018
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progressionJohn F Seymour, Robert Marcus, Andrew Davies, et al.
British Journal of Haematology|April 22, 2008
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patientsCarsten Hirt, Frank Schüler, Thomas Kiefer, et al.
Toxicology Letters|October 9, 2021
Use of in vitro metabolomics in NRK cells to help predicting nephrotoxicity and differentiating the MoA of nephrotoxicantsBarbara Birk, Volker Haake, Saskia Sperber, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Archives of Toxicology|October 2, 2017
Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cellsTzutzuy Ramirez, Alexander Strigun, Andreas Verlohner, et al.
Cell Biology and Toxicology|May 3, 2023
A high-throughput metabolomics in vitro platform for the characterization of hepatotoxicitySabina Ramirez-Hincapie, Barbara Birk, Philipp Ternes, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 31, 2022
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical TrialsJesse G Dixon, Çağlar Çağlayan, Dai Chihara, et al.
The New England Journal of Medicine|October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular LymphomaRobert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Blood|October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trialsCarla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Pageof 4